Eagle Asset Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $141M | Sell |
707,663
-258,692
| -27% | -$48.3M | 0.72% | 38 |
|
|
2024
Q2 | $165M | Sell |
966,355
-4,209
| -0.4% | -$697K | 0.88% | 18 |
|
|
2024
Q1 | $175M | Sell |
970,564
-24,390
| -2% | -$4.2M | 0.89% | 19 |
|
|
2023
Q4 | $154M | Sell |
994,954
-34,741
| -3% | -$5.06M | 0.83% | 28 |
|
|
2023
Q3 | $153M | Sell |
1,029,695
-25,049
| -2% | -$3.68M | 0.91% | 16 |
|
|
2023
Q2 | $142M | Sell |
1,054,744
-19,798
| -2% | -$2.9M | 0.79% | 32 |
|
|
2023
Q1 | $171M | Buy |
1,074,542
+119,530
| +13% | +$18.3M | 1% | 14 |
|
|
2022
Q4 | $155M | Buy |
955,012
+6,426
| +0.7% | +$985K | 0.95% | 19 |
|
|
2022
Q3 | $127M | Sell |
948,586
-6,536
| -0.7% | -$938K | 0.83% | 25 |
|
|
2022
Q2 | $146M | Sell |
955,122
-56,091
| -6% | -$8.57M | 0.92% | 16 |
|
|
2022
Q1 | $164M | Sell |
1,011,213
-226,165
| -18% | -$32.9M | 0.84% | 19 |
|
|
2021
Q4 | $168M | Buy |
1,237,378
+22,125
| +2% | +$2.61M | 0.74% | 32 |
|
|
2021
Q3 | $131M | Buy |
1,215,253
+81,578
| +7% | +$9.32M | 0.59% | 47 |
|
|
2021
Q2 | $128M | Buy |
1,133,675
+20,761
| +2% | +$2.34M | 0.55% | 59 |
|
|
2021
Q1 | $121M | Buy |
1,112,914
+842,576
| +312% | +$90.1M | 0.54% | 57 |
|
|
2020
Q4 | $29M | Buy |
270,338
+23,641
| +10% | +$2.27M | 0.16% | 189 |
|
|
2020
Q3 | $21.4M | Buy |
246,697
+5,011
| +2% | +$472K | 0.11% | 207 |
|
|
2020
Q2 | $23.3M | Sell |
241,686
-24,012
| -9% | -$2.11M | 0.13% | 198 |
|
|
2020
Q1 | $20.2M | Buy |
265,698
+173,748
| +189% | +$14.8M | 0.13% | 208 |
|
|
2019
Q4 | $8.14M | Buy |
91,950
+34,310
| +60% | +$2.85M | 0.04% | 341 |
|
|
2019
Q3 | $4.36M | Buy |
57,640
+519
| +0.9% | +$35.6K | 0.02% | 421 |
|
|
2019
Q2 | $4.15M | Buy |
57,121
+1,231
| +2% | +$96.8K | 0.02% | 424 |
|
|
2019
Q1 | $4.5M | Buy |
55,890
+1,407
| +3% | +$115K | 0.02% | 425 |
|
|
2018
Q4 | $5.02M | Sell |
54,483
-1,867
| -3% | -$164K | 0.03% | 383 |
|
|
2018
Q3 | $5.33M | Buy |
56,350
+1,172
| +2% | +$111K | 0.03% | 425 |
|
|
2018
Q2 | $5.11M | Buy |
55,178
+716
| +1% | +$69.9K | 0.03% | 418 |
|
|
2018
Q1 | $5.15M | Buy |
54,462
+165
| +0.3% | +$18.1K | 0.03% | 416 |
|
|
2017
Q4 | $5.96M | Sell |
54,297
-27,721
| -34% | -$2.61M | 0.03% | 403 |
|
|
2017
Q3 | $7.41M | Buy |
82,018
+78,326
| +2,122% | +$5.96M | 0.04% | 376 |
|
|
2017
Q2 | $267K | Buy |
3,692
+145
| +4% | +$9.75K | ﹤0.01% | 617 |
|
|
2017
Q1 | $231K | Buy |
+3,547
| New | +$223K | ﹤0.01% | 634 |
|
|
2016
Q2 | – | Sell |
-36,703
| Closed | -$2.1M | – | 626 |
|
|
2016
Q1 | $2.1M | Sell |
36,703
-66
| -0.2% | -$3.68K | 0.01% | 540 |
|
|
2015
Q4 | $2.18M | Sell |
36,769
-839
| -2% | -$48.3K | 0.01% | 538 |
|
|
2015
Q3 | $2.05M | Sell |
37,608
-34,661
| -48% | -$2.26M | 0.01% | 554 |
|
|
2015
Q2 | $4.86M | Buy |
72,269
+31,238
| +76% | +$2.04M | 0.03% | 434 |
|
|
2015
Q1 | $2.4M | Sell |
41,031
-318
| -0.8% | -$19.2K | 0.01% | 514 |
|
|
2014
Q4 | $2.71M | Sell |
41,349
-21,245
| -34% | -$1.34M | 0.02% | 507 |
|
|
2014
Q3 | $3.62M | Buy |
+62,594
| New | +$3.48M | 0.02% | 488 |
|
Other funds holding ABBV
Eagle Asset Management's ABBV Position: Q3 2024 in Review
Eagle Asset Management reduced its AbbVie (ABBV) stake by 27% in Q3 2024, selling an estimated $48.3M and leaving 707,663 shares worth $141M. The position accounts for 0.72% of the portfolio, ranked #38.
Eagle Asset Management first reported a position in ABBV in Q3 2014 and has held it in 38 quarters since. The position peaked at $175M in Q1 2024. 3,498 funds tracked by Wall St. Rank hold ABBV as of Q3 2024.
- Eagle Asset Management held 707,663 shares of AbbVie worth $141M as of Q3 2024.
- Eagle Asset Management sold 258,692 AbbVie shares in Q3 2024, an estimated $48.3M.
- AbbVie made up 0.72% of Eagle Asset Management's portfolio in Q3 2024, its #38 holding.
- Eagle Asset Management first reported a position in AbbVie in Q3 2014 and has held it in 38 quarters since.
- Eagle Asset Management's AbbVie position peaked at $175M in Q1 2024.
- 3,498 funds tracked by Wall St. Rank held AbbVie as of Q3 2024.
Based on Eagle Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.